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SUMMARY
For decades antimonials were the drugs of choice for the treatment of visceral leishmaniasis (VL), but the recent emergence
of resistance has made them redundant as ﬁrst-line therapy in the endemic VL region in the Indian subcontinent. The
application of other drugs has been limited due to adverse eﬀects, perceived high cost, need for parenteral administration
and increasing rate of treatment failures. Liposomal amphotericin B (AmB) andmiltefosine (MIL) have been positioned as
the eﬀective ﬁrst-line treatments; however, the number of monotherapy MIL-failures has increased after a decade of use.
Since no validated molecular resistance markers are yet available, monitoring and surveillance of changes in drug sensitiv-
ity and resistance still depends on standard phenotypic in vitro promastigote or amastigote susceptibility assays. Clinical
isolates displaying deﬁned MIL- or AmB-resistance are still fairly scarce and fundamental and applied research on resist-
ance mechanisms and dynamics remains largely dependent on laboratory-generated drug resistant strains. This review
addresses the various challenges associated with drug susceptibility and -resistance monitoring in VL, with particular
emphasis on the choice of strains, susceptibility model selection and standardization of procedures with speciﬁc read-
out parameters and well-deﬁned threshold criteria. The latter are essential to support surveillance systems and safeguard
the limited number of currently available antileishmanial drugs.
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INTRODUCTION: THE GROWING NEED TO DEFINE
RESISTANCE
Based on mortality and morbidity, leishmaniasis is
currently still one of the world’s most neglected trop-
ical infectious diseases (Houweling et al. 2016) with
the visceral form (VL – visceral leishmaniasis)
causing approximately 0·2–0·4 million cases and up
to 30 000 deaths worldwide annually (Alvar et al.
2012). However, the actual number of VL infected
individuals is probably higher due to underreporting
and delayed diagnosis (Gurunath et al. 2014). The
Indian subcontinent alone was responsible for over
60% of the global VL disease burden with almost
50% of all VL cases in Bihar state (India), making it
the VL ‘hotspot’ (Bhunia et al. 2013; Muniaraj,
2014). Although VL mainly strikes the populations
in poverty in developing countries, over the years it
has become an emerging problem due to a rise in
migration patterns, a lack of control measures and
the growing number of HIV/VL coinfections for
instance (Ready, 2014). Currently, treatment of
human VL relies on a limited number of drugs all
with issues that limit their widespread use. While
VL was mainly treated with pentavalent antimony
(SbV) formulations in the past (Chakravarty &
Sundar, 2010; Haldar et al. 2011), their ﬁrst-line
use in the Indian subcontinent was largely abandoned
due to the emergence of widespread SbV-resistance
(Muniaraj, 2014). Although liposomal amphotericin
B (AmB) (AmBisome®) is currently recommended
in the Indian subcontinent within a large-scale VL
elimination eﬀort, until recently its use was restricted
due its high cost, limited availability and the require-
ment for cold chain facilities. At present, a large eﬀort
is being made to make AmBisome® available at large-
scale in endemic areas. In 2011, Gilead partnered
with the World Health Organization (WHO) result-
ing in a large batch of AmBisome® that is now avail-
able at discounted prices in developing countries.
Following the 2012 London Declaration
(Balasegaram et al. 2012), it has even been donated
by Gilead via the WHO, currently making it the
drug of choice for the VL elimination programme
in the Indian subcontinent. In addition to its
enhanced availability, the KalaCORE programme
(www.kalacore.org) aims to improve access and sup-
ports cold-chains in India.
In the recent past, miltefosine (MIL) monother-
apy was proposed as an eﬀective and more aﬀordable
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alternative, while the use of paromomycin (PMM) is
limited to combinations with SbV in East Africa
(Davidson et al. 2009; Thakur et al. 2000) or in com-
bination with MIL as a proposed second-line treat-
ment in the Indian subcontinent (Sundar et al,
2011). However, several in vitro and in vivo labora-
tory studies indicated that development of resistance
against both drugs could be expected, even when
used in combination therapy (Seifert et al. 2003;
Garcia-Hernandez et al. 2012; Hendrickx et al.
2012, 2014). MIL-monotherapy was implemented
until 2014 as the ﬁrst-line option in the kala-azar
elimination programme (Jha et al. 2013). High
relapse rates combined with the possible limited
drug exposure in some patients (Rijal et al. 2013;
Dorlo et al. 2014) ultimately led to a revision of
this current VL treatment regimen. Although no
deﬁnite link with intrinsic drug resistance could be
established (Rijal et al. 2013; Carnielli et al. 2014;
Hendrickx et al. 2015a), the use of MIL-monother-
apy is now discouraged.
In addition to challenges with drug resistance in
human VL, the situation is generally comparable
for canine leishmaniasis (canL). While the use of
the drugs that are also used to treat human VL is dis-
couraged for canL treatment, there has been wide-
spread use of MIL in veterinary practice. This
deserves particular attention as it creates a signiﬁcant
additional selection drug pressure for Leishmania
infantum (Noli & Saridomichelakis, 2014). Since
no cure can be obtained, repeated treatments of
infected dogs could select for resistant parasites
and enhanced zoonotic transmission to man.
It is essential that in-depth research into the charac-
terization of the factors aﬀecting treatment eﬃcacy
and in particular identifying drug resistance mechan-
isms should acquire more momentum to provide
molecular markers for ongoing resistance surveillance
which, in turn, will give guidance to physicians and
the health community to draw up adapted treatment
policies. There is an urgent need to characterize and
distinguish between parasite- and host-related
eﬀects on drug eﬃcacy. Since a lot of variation in
drug susceptibility has already been described
between strains from diﬀerent geographical regions
(Hailu et al. 2010; Machado et al. 2010; Chrusciak-
Talhari et al. 2011; Soto et al. 2004, 2008) a reliable
and reproducible method is needed to discriminate
shifts in drug susceptibility and actual drug resistance
within parasite populations from the host pharmaco-
kinetic and immunological factors. Even though an
intensive search for easy-to-use molecular markers
has been pursued during the last decade, we still do
not have standard criteria and methodologies to
unequivocally deﬁne a parasite’s drug susceptibility.
The pivotal role of the patient (immunity, genetic
background, etc.) in post-treatment relapses should
not be overlooked either.
DRUG RESISTANCE MARKERS
When talking about drug resistance, it is important
to distinguish between drug susceptibility, drug sen-
sitivity and drug resistance. Drug susceptibility is
deﬁned as the response of a certain Leishmania
strain/isolate to a standard drug under deﬁned in
vitro conditions, whereas drug sensitivity implies
measuring the response of the strain/isolate to a
standard drug in vivo using predeﬁned doses, dose-
schedules, and including pharmacokinetics and
immune status of the host. Ineﬀectiveness of
killing organisms by what is considered a state-of-
the-art treatment generally refers to drug resistance.
Since drug susceptibility testing is quite labour-
intensive, expensive and time-consuming, access to
validated resistance markers that are easier to use in
routine laboratory settings would be highly desirable
(Croft et al. 2006; t’Kindt et al. 2010). In this respect,
numerous proteomic and metabolomic studies on
large sample sets of laboratory and clinical isolates
currently aim to identify putative resistance markers
and novel drug targets (Scheltema et al. 2010;
Downing et al. 2011; Vanaerschot et al. 2012b; Berg
et al. 2013; De Jesus et al. 2014). However, the
results of such studies are diﬃcult to interpret given
their dependence on the parasite stage and culture
conditions, and the general pleiotropic resistance
mechanisms expected (Silva et al. 2011). Molecular
characterization is further hampered by the highly
plastic nature of the Leishmania genome, as reﬂected
by its ability to swiftly modulate gene expression by
gene ampliﬁcation/deletion and to alter its chromo-
some ploidy in reaction to stress (Ubeda et al. 2008;
Leprohon et al. 2009; Brotherton et al. 2013).
Given the availability of SbV-resistant clinical iso-
lates, numerous studies have focused on identifying
molecular markers responsible for changes in Sb-sus-
ceptibility, revealing as the most reported targets
aquaglyceroporin 1 (AQP1) (Mandal et al. 2010;
Kumar et al. 2012) and the ATP-binding cassette
(ABC) transporter MRPA (Singh, 2006; Ashutosh
et al. 2007; Mittal et al. 2007; Mukherjee et al.
2007; Kumar et al. 2012), which play a role in drug
uptake and sequestration. Other targets suggested to
be involved in Sb-resistance are phosphoglycerate
kinase (PGK) implicated in glycolysis metabolism
(Kazemi-Rad et al. 2013), the multidrug-resistance
protein 1 (Mukherjee et al. 2013), the kinetoplastid
membrane protein (El et al. 2009), heat-shock
protein 83 (HSP83) (Vergnes et al. 2007), histone
H2A (Singh et al. 2010), γ-glutamylcysteine synthase
(Ashutosh et al. 2012), ornithine decarboxylase
(Mukherjee et al. 2007), mitogen-activated protein
kinase (Ashutosh et al. 2012; Kazemi-Rad et al.
2013) and protein tyrosine phosphatase (Kazemi-
Rad et al. 2013). Since variations in gene expression
do occur between diﬀerent strains and species,
recent studies recommend expression analysis of
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multiple genes as a valid biomarker to diﬀerentiate
Sb-resistance in clinical isolates (Kumar et al. 2012;
Imamura et al. 2016).
For MIL, several studies suggested genetic adap-
tations in the Leishmania donovani putative miltefo-
sine transporter (LdMT) and its cofactor LdRos3
(Perez-Victoria et al. 2003a, b; Perez-Victoria et al.
2006a; Seifert et al. 2007). However, identiﬁcation
of fully reliable molecular markers is still partly
hampered by the lack of in vivo deﬁned drug-resist-
ant clinical isolates (Rijal et al. 2013; Mondelaers
et al. 2016). Although reports on clinical resistance
have appeared for the other two used drugs PMM
and AmB (Purkait et al. 2012; Hendrickx et al.
2014), generally the number of clinical failure iso-
lates associated to drug resistance is still scarce,
hence most of our current knowledge on drug resist-
ance has been gathered using laboratory-derived
resistant and susceptible parasites. In addition,
most laboratory studies have focused on resistance-
selected promastigotes rather than the relevant intra-
cellular amastigote stage, which may conceal the real
predictive value of the ﬁndings.
DRUG SUSCEPTIBILITY TESTING
Diagnosis
Parasitological diagnosis in the patient still relies on
the microscopic examination of bone-marrow or
spleen aspirates accompanied by the establishment
of in vitro aspirate cultures of promastigotes (Sinha
et al. 1993; Mondal et al. 2010; Boelaert et al.
2014). Detection of drug resistance still relies on para-
site isolation and phenotypic susceptibility testing
(Sundar et al. 2014). Since these processes are compli-
cated (Fig. 1) and are hampered by safety risks, com-
plexity and slow generation of results (Maes et al.
2013; Boelaert et al. 2014), parasite isolation for diag-
nosis has been gradually replaced by non-invasive
molecular techniques or immunochromatographic
methods detecting Leishmania antigens or antibodies
in patient sera (WHO, 2010; Boelaert et al. 2014).
Microbiological testing
Given Leishmania’s digenetic life cycle, the para-
site’s drug susceptibility can be determined either
on the promastigote vector stage or the amastigote
mammalian stage. Most laboratories still routinely
establish drug susceptibility of clinical isolates on
the axenically cultured promastigote stage. By
exposing promastigotes to serial drug dilution
series, parasite viability can be read out quite easily
with Alamar blue, MTT or resazurin (Fumarola
et al. 2004; Maes et al. 2013). Although a correlation
can be found between promastigote and amastigote
susceptibility for some drugs (Kulshrestha et al.
2013), the intracellular amastigote model is still con-
sidered to be the gold standard in antileishmanial
drug susceptibility determination given the stage-
dependent drug eﬃcacy (Vermeersch et al. 2009). To
determine the intracellular amastigote susceptibility,
Fig. 1. Schematic overview of the pathway from the clinical setting with infected patient to the in vitro susceptibility
testing of the clinical ﬁeld isolate in the laboratory setting. (1) primary isolation from infected patient; (2) adaptation of the
parasite to in vitro culture; (3) susceptibility testing either on a/ promastigotes or b/ intracellular amastigotes; (4)
cryopreservation; (5) cloning.
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macrophages are infected with either metacyclic pro-
mastigotes (routinely available upon parasitological
diagnosis) or organ-derived amastigotes (generally
after adaptation to laboratory rodents). After infection,
serial drug dilutions are added to the infected cells and
the amastigote burden reduction compared to
untreated control cells is determined microscopically,
making this assay time-consuming, labour-intensive
and therefore quite expensive. Given the stage-
speciﬁc diﬀerence in drug susceptibility, the use of
axenic amastigotes is still under debate as there are
diﬀerences in drug susceptibility compared with
the intracellular amastigote (Gupta et al. 2001;
Vermeersch et al. 2009). Although assays using lumi-
nescent, ﬂuorescent or colorimetric assays are useful
for drug screening, the genetic manipulation of the
isolate and time-in-culture makes this approach
redundant in this context. When it comes to designing
an assay for intracellular amastigotes, the use ofmacro-
phages of diverse origins (e.g. diﬀerent cell lines vs
primary macrophages) (Seifert et al. 2010), diﬀerent
culture media and the use of diﬀerent methods of
infection and treatment protocols all contribute to
the fact that direct comparison of susceptibility data
between diﬀerent laboratories is virtually impossible
without agreed standardization of protocols and ana-
lysis (Table 1).
Deﬁning drug resistance
In the absence of easy ways to assess in vivo resist-
ance due to the large number of factors aﬀecting
host response, in vitro techniques are generally con-
sidered for deﬁning drug resistance. It speciﬁcally
refers to a particular decrease of susceptibility of a
certain Leishmania strain or species to a standard
drug under the same predeﬁned in vitro conditions
and falsely assumes that the initial susceptibility of
the parasite population before treatment is always
known (Croft et al. 2006). In order to deﬁne ‘in
vitro’ resistance, a drug concentration ‘threshold’
should be selected that is able to distinguish a sus-
ceptible population from a non-susceptible one.
Concentration thresholds or putative molecular
markers can only be deﬁned after extensive suscepti-
bility studies on hundreds or thousands of clinical
isolates over varying regions, as has been established
for malaria by the WorldWide Antimalarial
Resistance Network (WWARN) (www.wwarn.org)
and for drug resistant bacteria in Europe by the
European Committee on Antimicrobial Susceptibility
Testing (EUCAST). Tentatively proposed ‘threshold’
values of the current antileishmanial reference drugs
SbV, AmB, MIL and PMM for all species of the
L. donovani complex are summarized in Table 2
(Maes et al. 2013). As an alternative, the use of an activ-
ity or resistance index has been suggested, expressing
the fold decrease of susceptibility of a certain isolate
compared with a drug susceptible reference isolate
(Yardley et al. 2006; Inocencio da Luz et al. 2009).
For some drugs, this approach is severely hampered
by the natural variations in susceptibility of drug-
responsive clinical isolates, precluding deﬁnition of
clear cut-oﬀ values for resistance.
Hurdles encountered during in vitro susceptibility
testing
Deﬁning a resistance ‘threshold’ concentration is
further complicated by the known variation in
species and strain drug-responsiveness, making the
establishment of a single ‘threshold value extremely
challenging. Next to these interspecies diﬀerences
and the genetic diversity linked to geographical
background, the polyclonal nature of strains
(Fernandez et al. 2012; Hendrickx et al. 2012) also
precludes extension of conclusions on susceptibil-
ity/resistance between species and hence enforces
similar susceptibility studies for every Leishmania
species and strain (Gouzelou et al. 2013).
Drug susceptibility testing of ﬁeld isolates is logic-
ally assumed to be the most useful method to predict
treatment outcome, as has been established for anti-
biotics in bacterial infections (Boothe, 2010) and for
malaria (Duru et al. 2015). However, treatment
failure is a complex interplay between various factors
(Table 3) related to either drug, parasite or host, and
is thus not necessarily exclusively linked to drug sus-
ceptibility (Vanaerschot et al. 2014). For example for
SbV, a correlation was found between treatment
outcome and the in vitro amastigote susceptibility
proﬁle of ﬁeld isolates ranging from susceptible (S/S)
over intermediate (R/S) to resistant (R/R). Actually,
R/R cases could be linked to non-responders or
relapse cases while S/S strains were linked to cure.
The intermediate R/S proﬁle was linked to an
increased risk for R/R development (Inocencio da
Luz et al. 2009). On the other hand for MIL, in vitro
susceptibility data could not be used to predict treat-
ment failure (Hendrickx et al. 2015a) even though
Table 1. Factors involved in the proposed
standardization
1. Species, strain of Leishmania
2. Methodology
A. Parasite stage
B. Host cell type
3. Medium
4. Inoculum
5. Incubation temperature
6. Incubation time
7. Compound/drug formulation
8. Endpoint
9. Quality control
A. Number of replicates/repeats
B. Reference drugs and acceptable range
C. Background signal ratio
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some studies do suggest a weak link between in vitro
susceptibility and treatment outcome (Bhandari et al.
2012; Rijal et al. 2013). Also the promastigote back-
transformation assay, initially proposed as an alterna-
tive to assess treatment outcome (Hendrickx et al.
2014) could not diﬀerentiate between responder and
relapse patients when evaluated on a larger set of clin-
ical isolates (Hendrickx et al. 2015a).
Probably even more important is the fact that,
although several labs worldwide have been involved
in susceptibility determination of clinical isolates,
drug susceptibility values remain fairly inconclusive
due the lack of validated standard operating proce-
dures (SOPs), precluding direct comparison of
results between laboratories mainly due to large vari-
ation in susceptibility assay protocols and endpoints.
Even for susceptibility research within the same
laboratory, either for antimicrobials, antiparasitics
or antifungals, results may vary signiﬁcantly in
time and between replicate tests (Rex et al. 1997).
It is therefore essential to improve harmonization
of laboratory assays while also recognizing that this
may not be straightforward. A panel of SOPs and
well-deﬁned procedures for quality control would
allow better comparison of results, strengthen statis-
tical analysis and could eventually contribute to estab-
lish well-deﬁned endpoints and drug resistance
breakpoints. Formalaria, for example, a special resist-
ance network was founded (WWARN: WorldWide
Antimalarial resistance Network; www.wwarn.org;
now operating under the auspices of the newly estab-
lished Infectious Diseases Data Observatory –
IDDO) which focuses on the surveillance of drug
eﬃcacy by providing detailed procedures for drug
preparation, experimental protocols, a tool to gener-
ate in vitro IC50 and IC90 values, and literature
reviews thereby ensuring that all information gener-
ated on antimalarial drug resistance remains of the
highest quality and are searchable in a single
place (Lourens et al. 2010; Sibley & Price, 2012;
Table 2. ‘Breakpoint’ estimatesa for categorizing drug-susceptibility and drug resistance against antimonials
(Sb), miltefosine (MIL), paromomycin (PMM) and amphotericin B (AmB)
Promastigotes
(axenic)
Amastigotes (primary mouse
macrophages)
Susceptibility limits (IC50
estimates)
Cytotoxicity
(MRC-5)
Drugb IC50 IC50 sensitive resistant CC50
SbV >77 10–15 <20 >70 >64
SbIII 40–50 5–6 <15 >70 >64
MIL 2–5 3–6 <10 >25c 32
PMM 15–25 40–50 <60 >150c >500
AmB 0·1–0·3 0·01–0·03 <0·5 (>2)c >8
a Based on results obtained with sensitive reference strains (L. donovani MHOM/ET/67/L82 and L. infantum MHOM/
MA/67/ITMAP263).
b μg mL−1 for Sb, μM for other compounds.
c at present, no resistant isolates from treated patients are available yet.
Table 3. Overview of factors involved in VL disease progression and treatment failure
Factor References
Host
Immunological factors (Jarvis & Lockwood, 2013; Ostyn et al. 2014)
Pharmacokinetics (Ostyn et al. 2014)
Genetics (Blackwell, 1996; Castellucci et al. 2014)
Reinfection (Rijal et al. 2013)
Environment (Perry et al. 2013)
Drug
Drug quality (Dorlo et al. 2012a, b)
Intrinsic drug properties (e.g. T1/2) (Hastings et al. 2002)
Treatment duration (Geli et al. 2012)
Non-compliance (Rijal et al. 2013)
Parasite
Lower intrinsic susceptibility to the drug (Singh et al. 2006; Rijal et al. 2013)
– gene ampliﬁcation of drug target enzymes
– structural and functional modiﬁcations of drug target enzymes (Mondelaers et al. 2016)
– decrease in intracellular drug concentration due to extrusion by
speciﬁc transporters
Higher parasite ﬁtness (Vanaerschot et al. 2014; Hendrickx et al. 2015b;
Hendrickx et al. 2016)
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Woodrow et al. 2013). Furthermore, the development
of external quality assurance programmes has pro-
vided critical tools to compare results across laborator-
ies (Lourens et al. 2010; Lourens et al. 2014).
Unfortunately, there have been few attempts in
leishmaniasis to tackle the innumerable challenges to
standardize laboratory procedures from the initial
stages of parasite isolation and sample propagation,
even though some basic variability can never be
avoided (Fig. 1). While the introduction of an activity
index provided a useful tool to compare experiments
between laboratories and between diﬀerent experi-
ment series (Yardley et al. 2006), implementation
of stricter ‘drug susceptibility procedures’ will add
to the quality of monitoring programmes in the ﬁeld
and even facilitate discovery research for novel
antileishmanial drugs. Despite several calls for
standardization in the past (Croft, 2001; Croft et al.
2006), endpoint criteria and assays required to
obtain qualitative data have so far only been deﬁned
for natural products (Cos et al. 2006), although the
same rules could obviously also be used for small
molecules.
Launching a harmonization initiative
The added value of standardized Leishmania
research procedures is obvious. The ﬁrst required
step is the creation of task force or working group
to bring experts from academia, diagnostic labora-
tories, the clinic and public health together with
those who have pioneered similar programmes in
malaria and microbial infections, to establish and
disseminate a critical set of procedures and analytical
tools that will deﬁne acceptable levels of harmoniza-
tion and uniformity between diﬀerent laboratories.
To start this process, a ﬁrst proposal of some basic pro-
cedures concerning diagnostic sampling and follow-up
standard laboratory procedures is presented in the
Supplementary Material Section (Table 4). The
various eﬀorts by the WWARN platform enabled a
better comprehension of the factors aﬀecting drug
eﬃcacy which subsequently has been corrected
by policy changes. For example,WWARNdeveloped
a unique on-linemodel (http://www.wwarn.org/tools-
resources/external-quality-assurance) to facilitate
individual patient data sharing and engaged over 260
partners around the world, comprised research
institutions, governmental and non-governmental
organizations, product development partnerships
and pharmaceutical companies. These examples of
impact should encourage a prompt response from
the Leishmania research community and launch a
similar action plan in support of the elimination of
VL from India, Nepal and Bangladesh by 2017 as
public health priority (WHO, 2015).
Beyond this initial action, there are still some aspects
that deserve particular consideration in drug resistance
research. Given the paucity of drug-resistant clinical
isolates, resistance research for most drugs has
mainly relied on laboratory-selected strains or on
unmatched clinical isolates, hence drifting away from
a comparable genetic and phenotypic background.
The lack of paired pre- and post-treatment isolates
obscures correct interpretation of shifting drug suscep-
tibility. Additionally, the long adaptation process from
initial isolation until evaluation in the laboratory
further impairs the acquisition of representative clin-
ical isolates, partly related to a changing virulence
and genomic proﬁle (Silva et al. 2011; Moreira et al.
2012). Although previous research already proposed
preconditioning of promastigotes as a way to increase
and synchronize infectivity and virulence in vitro
(Inocencio da Luz et al. 2009), its systematic use
may be debatable as it will aﬀect the original strain-
speciﬁc phenotypic characteristics.
As already stated, most research has focused on
SbV-resistance as large numbers of Sb-resistant clin-
ical isolates were indeed available in India, making
laboratory selection of Sb-resistance uncommon.
However, as there are relatively few novel antileish-
manial compounds in development (www.dndi.org),
greater vigilance is warranted and attention must be
paid to proactively address treatment failures and
relapses in an attempt to contain the risk of drug
resistance. Laboratory selection of resistance
strains has long been established as a valid tool to
study phenotypic changes accompanied by the selec-
tion of drug resistance and to unravel underlying
resistance mechanisms. The most important beneﬁt
of experimental resistance selection is the availability
of matched pairs in which the acquired drug resist-
ance undeniably results from the incurred genomic,
proteomic and phenotypic variations. However, the
relevance of laboratory selected resistant strains
exposed to constant drug concentrations in plastic
Table 4. Overview of the operating procedures presented in the supplementary material section
Procedure Title
1 Biphasic culture media for primary isolation of promastigotes from spleen- or bone-marrow aspirates
2 Monophasic culture media for axenisation of promastigotes
3 Cryopreservation of Leishmania promastigotes
4 Cloning of Leishmania promastigotes
5 Preparation of stock solutions of antileishmania reference drugs
6 Drug-susceptibility assay for promastigotes
7 Drug-susceptibility assay for intracellular amastigotes
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vessels to the ‘real world’ pharmacokinetic variation
of drug concentration and diﬀerent physiological con-
ditions (e.g. oxygen tension) in diﬀerent tissues has
not been established (MacGowan et al. 2001).
Many laboratories still select for drug resistance
on the promastigote vector stage by cyclic exposure
to serially increasing drug concentrations (Maarouf
et al. 1998; Seifert et al. 2003; Perez-Victoria et al.
2006b; Bhandari et al. 2014). Selection on axenic
promastigotes has already proven to result in
diﬀerent resistance mechanisms than the ones
observed in the clinical setting (Goyeneche-Patino
et al. 2008). Although much more complex and
laborious, selection of MIL- and PMM-resistance
at the intracellular amastigote level has proven suc-
cessful both in vitro and in vivo (Hendrickx et al.
2012, 2015c). While the lack of active amastigote
replication during successive in vitro treatment
cycles could suggest passive selection of less suscep-
tible strains (Hendrickx et al. 2015d), the protocol-
dependent outcome for PMM strongly endorses
the need to use intracellular amastigotes in drug
resistance research (Hendrickx et al. 2014, 2012) or
at least reach for proper validation when using pro-
mastigotes. While overlooking the potential involve-
ment of sand ﬂy factors in transmission and
infectivity (Bates, 2007) and still requiring large-
scale validation with actual resistant clinical isolates,
the intracellular amastigote laboratory models do
oﬀer a more representative and predictive alternative
to promastigote-based models. Although MIL-
resistance could be generated relatively easily at the
promastigote level (Perez-Victoria et al. 2003a;
Seifert et al. 2003), it should be mentioned that the
amastigote-based protocols resulted in the selection
of only one MIL-resistant isolate of L. infantum
(Hendrickx et al. 2015d), which might be suggestive
for strain/species-speciﬁcity.
POSSIBLE EPIDEMIOLOGIC IMPLICATIONS OF
RESISTANCE
Selection of drug resistance in most organisms gen-
erally results in particular disadvantages with
regard to successful survival, reproduction and/or
transmission between hosts in a given environment,
better known as ‘ﬁtness’ (Natera et al. 2007; Borrell
& Gagneux, 2009; Orr, 2009; Ait-Oudhia et al.
2011). For Leishmania, ﬁtness is mainly reﬂected
by the parasite’s growth potential, infectivity and
its ability to be transmitted (Natera et al. 2007).
The speciﬁc impact of resistance remains debatable
and likely depends on the particular drug and para-
site species (Kink & Chang, 1987; Detke et al.
1988; Gazola et al. 2001; Al-Mohammed et al.
2005). Several studies indicated enhanced infectiv-
ity, metacyclogenesis and transmission in Sb-
resistant parasites (Vanaerschot et al. 2012a). Next
to the high selection pressure associated with
anthroponotic transmission, this increased parasite
ﬁtness might partly explain the widespread Sb-
resistance in the Indian subcontinent (Ouakad
et al. 2011; Vanaerschot et al. 2011, 2010). As
already mentioned, correct interpretation of such
studies may be challenging since they compared
sample sets of unpaired isolates with diﬀerent geno-
typic and phenotypic background traits (Laurent
et al. 2007). Since Leishmania strains are heteroge-
neous and show genomic plasticity, the use of
wild-type (WT) parent and directly derived drug-
resistant lines will rule out the involvement of
factors other than an altered drug susceptibility
phenotype. At present, this has only been achieved
with laboratory-selected resistant strains.
For PMM, increased ﬁtness was observed in a
L. donovani promastigote-selected strain (Bhandari
et al. 2014) and further corroborated in an in vitro
L. infantum amastigote-selected clinical isolate
(Hendrickx et al. 2016). However, in the latter
study no obvious ﬁtness beneﬁt could be detected in
promastigotes, once again endorsing again the proto-
col-dependent and possibly species-dependent
outcome of selection (Hendrickx et al. 2016). The
potential ﬁtness beneﬁt on intracellular amastigote
replication and the enhanced defence against oxida-
tive and nitrosative stress, combined with the fairly
rapid selection of PMM-resistance (Hendrickx et al.
2014, 2012), endorse that PMM should only be
used in combination therapy. On the other hand for
MIL, resistance selection on amastigotes revealed
that resistance may arise much slower than originally
anticipated (Hendrickx et al. 2014) and that contrary
to previous ﬁndings (Rai et al. 2013), the spread of
primary MIL-resistant parasites in the ﬁeld may be
hampered by ﬁtness disadvantages (Hendrickx et al.
2016). Although the possibility of decreased ﬁtness
may seem somewhat reassuring, the increasing
number of MIL-treatment failures is nevertheless
alarming particularly since the underlying nature of
treatment failure still remains largely unidentiﬁed.
Studies suggest that treatment failures might be
linked to MIL’s pharmacokinetic properties, poor
compliance linked to the long treatment regimen
and/or a reduced drug exposure (Rijal et al. 2013;
Dorlo et al. 2014). However, repetitive MIL-treat-
ment in relapse patients would certainly expedite
the emergence of primary MIL-resistance. This is
particularly worrying for L. infantum, which is
highly prevalent in HIV co-infected patients and in
canL, both conditions which are repeatedly treated
with MIL even though complete parasite eradication
cannot be achieved, thereby creating a huge parasite
reservoir subject to MIL-exposure and resistance
selection (Noli & Saridomichelakis, 2014; van
Griensven et al. 2014). Of particular concern is that
the few available MIL-resistant isolates (either clin-
ical isolates or in vitro selected on the amastigote
level) are indeed all L. infantum.
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Concluding remarks
Monitoring and surveillance of drug sensitivity and
resistance are essential to safeguard current treatment
options and to establish models for the introduction
of new drugs in the future. To discriminate resistant
and susceptible strains, a clear deﬁnition of drug
resistance with establishment of resistance ‘break-
points’ is deﬁnitely needed. Since no validated
genomic resistance markers are yet available, resist-
ance monitoring will continue to depend on standard
in vitro parasite susceptibility testing that should
focus on the intracellular amastigote whenever pos-
sible and better standardized in vivo assessment.
The current lack of shared procedures should be
addressed with priority to allow correct interpretation
and comparison of drug susceptibility studies
between labs. In addition, monitoring and surveil-
lance of Leishmania resistance in the ﬁeld should
deﬁnitely include large sample sizes of matched pre-
treatment and post-treatment isolates.
Large-scale implementation of particular SOPs
will be challenging and require a time and logistic
organization. The present paper is a ﬁrst tentative
proposal to launch a harmonization initiative for
particular basic and applied Leishmania research
procedures. Obviously, this proposed set will have
to be disseminated and discussed with the whole
Leishmania research community at international con-
ferences and within network groups (for example,
WorldLeish) to acquire input and practical feedback
to enable a widely feasible set of recommendations.
Through collaborations with the WHO Neglected
Tropical Diseases Department (WHO-NTD) and
the WHO’s Special Programme for Research and
Training in Tropical Diseases (WHO-TDR), per-
formance of elimination and control programmes at
country level may become enhanced. A special con-
sortium has already been founded by the Bill and
Melinda Gates Foundation to ensure suitable surveil-
lance measures to sustain VL elimination In the
Indian subcontinent. Joining all these various eﬀorts
should eventually pay oﬀ and lead to more reliable
and comparable laboratory results that will inform
the leishmaniasis community worldwide on the
eﬃcacy of the current antileishmanial drugs and the
emergence and spread of drug resistance.
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